Biotech IV Monitor

DFTX — Definium Therapeutics Inc.

$4.7B market cap · 1 upcoming readout tracked

Clinical trial readout dates for Definium Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is September 2027.

Next readoutSeptember 2027in ~10 months
Upcoming readouts11 Phase 3
Market cap$4.7B
Cash & investments$1.05B~21 quarters at last loss rate
Recent 8-K filings1latest 2026-11-09

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 3 DT120
Generalized Anxiety Disorder · NCT06809595
August 2026
Primary data collected
Phase 3 DT120
Generalized Anxiety Disorder · NCT06741228
July 2026
Primary data collected
Phase 3 DT120
Major Depressive Disorder · NCT06941844
May 2026
Primary data collected

Upcoming readouts

Phase 3 DT120
Major Depressive Disorder · NCT07592689
September 2027
Recruiting

Cash position

Definium Therapeutics Inc. reported $1.05B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $51M; at that rate the cash would last about 21 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-09

Companies working on similar indications

Discussion

No messages yet. If you follow DFTX, you can start the conversation.
Track DFTX in real time
See live implied volatility for DFTX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on DFTX
Contact — questions or corrections about DFTX: dukeupt@gmail.com